您当前所在的位置:首页 > 产品中心 > 产品详细信息
1062159-35-6 分子结构
点击图片或这里关闭

5-[4-(morpholin-4-yl)-1-[1-(pyridin-3-ylmethyl)piperidin-4-yl]-1H-pyrazolo[3,4-d]pyrimidin-6-yl]-1H-indole

ChemBase编号:73139
分子式:C28H30N8O
平均质量:494.5908
单一同位素质量:494.25425762
SMILES和InChIs

SMILES:
c12c(ccc(c1)c1nc3c(c(n1)N1CCOCC1)cnn3C1CCN(CC1)Cc1cccnc1)[nH]cc2
Canonical SMILES:
O1CCN(CC1)c1nc(nc2c1cnn2C1CCN(CC1)Cc1cccnc1)c1ccc2c(c1)cc[nH]2
InChI:
InChI=1S/C28H30N8O/c1-2-20(17-29-8-1)19-34-10-6-23(7-11-34)36-28-24(18-31-36)27(35-12-14-37-15-13-35)32-26(33-28)22-3-4-25-21(16-22)5-9-30-25/h1-5,8-9,16-18,23,30H,6-7,10-15,19H2
InChIKey:
FPEIJQLXFHKLJV-UHFFFAOYSA-N

引用这个纪录

CBID:73139 http://www.chembase.cn/molecule-73139.html

Collapse All Expand All

名称和登记号

名称和登记号

名称 登记号
IUPAC标准名
5-[4-(morpholin-4-yl)-1-[1-(pyridin-3-ylmethyl)piperidin-4-yl]-1H-pyrazolo[3,4-d]pyrimidin-6-yl]-1H-indole
IUPAC传统名
5-[4-(morpholin-4-yl)-1-[1-(pyridin-3-ylmethyl)piperidin-4-yl]pyrazolo[3,4-d]pyrimidin-6-yl]-1H-indole
别名
WAY-600
CAS号
1062159-35-6
PubChem SID
162038059
PubChem CID
25229526

数据来源

数据来源

所有数据来源 商品来源 非商品来源
数据来源 数据ID 价格
Selleck Chemicals
S2689 external link 加入购物车 请登录
数据来源 数据ID
PubChem 25229526 external link

理论计算性质

理论计算性质

JChem
质子受体 质子供体
LogD (pH = 5.5) 0.32666102  LogD (pH = 7.4) 2.3777094 
Log P 3.3716104  摩尔折射率 166.127 cm3
极化性 56.622383 Å3 极化表面积 87.99 Å2
可自由旋转的化学键 里宾斯基五规则 true 
Acid pKa 15.840893 

分子性质

分子性质

安全信息 药理学性质 产品相关信息 生物活性(PubChem)
保存条件
-20°C expand 查看数据来源
作用靶点
mTOR expand 查看数据来源
成盐信息
Free Base expand 查看数据来源

详细说明

详细说明

Selleck Chemicals Selleck Chemicals
Selleck Chemicals -  S2689 external link
Biological Activity
Description WAY-600 is a potent, ATP-competitive and selective inhibitor of mTOR with IC50 of 9 nM.
Targets mTOR
IC50 9 nM [1]
In Vitro Immune-complex kinase assay shows mTORC2-specific substrate His6-AKT or the mTORC1 substrate His6-S6K is dose dependently inhibited by WAY-600. WAY-600 globally inhibits mTOR signaling and AKT function in cellular models dose dependently. WAY-600 profoundly inhibits cap-dependent and global protein synthesis in MDA361, human breast cancer cells. WAY-600 shows antiproliferative effects in various cancer cell lines involving G1 cell cycle arrest and selective apoptosis. WAY-600 down-regulate angiogenic factors, VEGF and HIF-1α, in U87MG, MDA361 and LNCap cells. [1]
In Vivo
Clinical Trials
Features
Protocol
Kinase Assay [1]
DELFIA Format of Purified FLAG-TOR The routine assays with purified FLAG-TOR (FL and 3.5) are performed in 96-well plates as follows. Enzymes are first diluted in kinase assay buffer (10 mM Hepes (pH 7.4), 50 mM NaCl, 50 mM β-glycerophosphate, 10 mM MnCl2, 0.5 mM DTT, 0.25 lM microcystin LR, and 100 lg/mL BSA). To each well, 12 μL of the diluted enzyme is mixed briefly with 0.5 μL test inhibitor or control vehicle dimethyl sulfoxide (DMSO). The kinase reaction is initiated by adding 12.5 μL kinase assay buffer containing ATP and His6-S6K to give a final reaction volume of 25 μL containing 800 ng/mL FLAG-TOR, 100 μM ATP, and 1.25 μM His6-S6K. The reaction plate is incubated for 2 hours (linear at 1–6 hour) at room temperature with gentle shaking and then terminated by adding 25 μL Stop buffer (20 mM Hepes (pH 7.4), 20 mM EDTA, and 20 mM EGTA). The DELFIA detection of the phosphorylated (Thr-389) His6-S6Kis performed at room temperature using a monoclonal anti-P(T389)- p70S6K antibody (1A5) labeled with Europium-N1- ITC (Eu) (10.4 Eu per antibody). Fortyfive microliters of the terminated kinase reaction mixture are transferred to a MaxiSorp plate containing 55 μL PBS. The His6-S6K is allowed to attach for 2 hour after which the wells are aspirated and washed once with PBS. One hundred microliters of DELFIA buffer with 40 ng/mL Eu-P(T389)-S6K antibody is added. The antibody binding is continued for 1 hour with gentle agitation. The wells are then aspirated and washed four times with PBS containing 0.05% Tween 20 (PBST). One hundred microliters of DELFIA Enhancement solution is added to each well and the plates are read in a PerkinElmer Victor model plate reader. Data obtained are used to calculate enzymatic activity and enzyme inhibition by potential inhibitors.
Cell Assay [1]
Cell Lines MDA361, U87MG, HCT116, LNCap and HT29 cells
Concentrations 0-100 μM
Incubation Time 24 or 48 hours
Methods For cell cycle analysis, cells are seeded in 96-well culture plates at 10,000 cells per well for 24 hours, treated with various inhibitors for 24 hours or 48 hours. Following treatment, cells are harvested, washed with PBS and fixed overnight at -20 °C in 70% ethanol. Cells are washed, stained with propidium iodide and analyzed for cell cycle profile (acquired 5000 cells/well) on Guava PCA-96 instrument according to the Guava Cell Cycle Protocol.
References
[1] Yu K, et al, Cancer Res, 2009, 69(15), 6232-6240.

参考文献

参考文献

供应商提供 Google Scholar IconGoogle Scholar PubMed iconPubMed Google Books IconGoogle Books
正在搜索,请耐心等待...(如果遇到网页错误或者长时间没有结果,请刷新页面[F5])

专利

专利

PubChem iconPubChem Patent Google Patent Search IconGoogle Patent

互联网资源

互联网资源

百度图标百度 google iconGoogle